Mizuho Securities USA LLC Acquires 6,952 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mizuho Securities USA LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 46.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,014 shares of the medical equipment provider’s stock after acquiring an additional 6,952 shares during the quarter. Mizuho Securities USA LLC’s holdings in Hologic were worth $1,587,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Sciencast Management LP acquired a new stake in Hologic in the fourth quarter worth $694,000. TD Private Client Wealth LLC boosted its position in shares of Hologic by 47.5% during the 4th quarter. TD Private Client Wealth LLC now owns 7,115 shares of the medical equipment provider’s stock worth $513,000 after purchasing an additional 2,290 shares in the last quarter. Blueshift Asset Management LLC bought a new stake in Hologic in the 4th quarter valued at about $546,000. iA Global Asset Management Inc. raised its stake in Hologic by 49.7% during the 4th quarter. iA Global Asset Management Inc. now owns 13,398 shares of the medical equipment provider’s stock worth $966,000 after buying an additional 4,448 shares during the period. Finally, Teacher Retirement System of Texas boosted its holdings in Hologic by 82.9% in the fourth quarter. Teacher Retirement System of Texas now owns 649,883 shares of the medical equipment provider’s stock worth $46,850,000 after acquiring an additional 294,538 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of Hologic stock opened at $60.80 on Wednesday. The business’s fifty day simple moving average is $65.70 and its 200 day simple moving average is $73.66. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The firm has a market capitalization of $13.64 billion, a P/E ratio of 19.18, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. William Blair restated an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Morgan Stanley dropped their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, Royal Bank of Canada dropped their price target on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.